Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. nerve damage
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • This Year
  • Older

Nerve Damage Articles & Analysis

30 news found

Ace Therapeutics Launches In Vivo Models of Diabetes Mellitus to Enhance Diabetes Research Outcomes

Ace Therapeutics Launches In Vivo Models of Diabetes Mellitus to Enhance Diabetes Research Outcomes

Diabetes mellitus, a chronic condition characterized by elevated blood sugar levels, affects millions worldwide and poses serious health risks including cardiovascular disease, kidney failure, and nerve damage. As the prevalence of diabetes continues to rise, there is an urgent need for advanced research models that can accurately simulate the disease and ...

ByAce Therapeutics


Microneedle Market Projected to Reach $1.3 Billion by 2028, Reveals Latest BCC Research Study

Microneedle Market Projected to Reach $1.3 Billion by 2028, Reveals Latest BCC Research Study

Boston: Microneedle technology, driven by high demand in dermatologic procedures and its versatile applications in drug delivery, vaccine administration, and disease diagnostics, faces challenges in its complex manufacturing process. Ongoing research and numerous products in development make this market dynamic for newcomers entering the field. “According to the latest BCC Research study, ...

ByBCC Research


Ionis Announces Fda Acceptance Of New Drug Application For Eplontersen For The Treatment Of Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (Attrv-Pn)

Ionis Announces Fda Acceptance Of New Drug Application For Eplontersen For The Treatment Of Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (Attrv-Pn)

Patients with ATTRv-PN experience ongoing debilitating nerve damage throughout their body resulting in the progressive loss of motor function. ...

ByHeart Failure Society of America, Inc. (HFSA)


Liposomal Bupivacaine (Bupigel) Demonstrates Minimal Local Nerve Toxicity in a Rabbit Functional Model

Liposomal Bupivacaine (Bupigel) Demonstrates Minimal Local Nerve Toxicity in a Rabbit Functional Model

Nerve conduction studies and needle electromyography two weeks after perineural administration showed signs of neural damage after injection of free lidocaine and bupivacaine, while there was no sign of neural damage after injection with saline, demonstrating the validity of the method. This test also did not show evidence of motor or sensory ...

ByVirpax Pharmaceuticals


World Diabetes Day

World Diabetes Day

If left untreated, this can lead to serious complications such as heart attack, stroke, obesity, eye disease, kidney disease and nerve damage. World Diabetes Day is held on the 14th of November yearly to mark the birthday of Sir Frederick Banting, the co-founder of insulin. ...

ByNeurovalens Limited


Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference

Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Association Annual Conference

High blood glucose can lead to diabetic ketoacidosis and over time, to complications such as kidney disease/failure, eye disease (including vision loss), heart disease, stroke, nerve damage and even death. Due to the limitations and complexities of insulin delivery systems, it can be difficult to achieve and maintain balance in glucose control in people with ...

ByVertex Pharmaceuticals


Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes

Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type 1 Diabetes

High blood glucose can lead to diabetic ketoacidosis and over time, to complications such as kidney disease/failure, eye disease (including vision loss), heart disease, stroke, nerve damage and even death. Due to the limitations and complexities of insulin delivery systems, it can be difficult to achieve and maintain balance in glucose control in people with ...

ByVertex Pharmaceuticals


It All Starts With Patient Safety at Medovate

It All Starts With Patient Safety at Medovate

This revolutionary new system for regional anaesthesia has been developed in partnership with clinicians from The Queen Elizabeth Hospital King’s Lynn NHS Foundation Trust in the United Kingdom. Mitigating for nerve damage during regional anaesthesia through innovation The concept for the SAFIRA® system was born from observations made on the clinical ...

ByMedovate


Medovate Announces Us Distribution Agreement with Mercury Medical® For Safira®

Medovate Announces Us Distribution Agreement with Mercury Medical® For Safira®

” Developed with clinicians working in the UK’s NHS to promote safer injection during single shot regional anesthesia peripheral nerve block procedures, the SAFIRA® system transforms regional anesthesia into a one-person procedure, giving the anesthesiologist full control of the injection at all times. It also includes a built-in safety mechanism to automatically ...

ByMedovate


Axogen to Participate at Upcoming Investor Conferences

Axogen to Participate at Upcoming Investor Conferences

About Axogen Axogen (AXGN) is the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral ...

ByAxogen (AXGN)


Axogen, Inc. to Report Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call on February 22, 2022

Axogen, Inc. to Report Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call on February 22, 2022

About Axogen Axogen (AXGN) is the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral ...

ByAxogen (AXGN)


BlueRock Therapeutics Announces First Patient Dosed in Canada in Phase 1 Trial in Patients with Advanced Parkinson’s Disease

BlueRock Therapeutics Announces First Patient Dosed in Canada in Phase 1 Trial in Patients with Advanced Parkinson’s Disease

About Parkinson’s Disease Parkinson’s disease is a progressive neurodegenerative disorder caused by nerve cell damage in the brain, leading to decreased dopamine levels. ...

ByBlueRock Therapeutics


BlueRock Therapeutics Announces Closeout of First Cohort in Phase 1 Trial in Patients with Advanced Parkinson’s Disease

BlueRock Therapeutics Announces Closeout of First Cohort in Phase 1 Trial in Patients with Advanced Parkinson’s Disease

About Parkinson’s Disease Parkinson’s disease is a progressive neurodegenerative disorder caused by nerve cell damage in the brain, leading to decreased dopamine levels. ...

ByBlueRock Therapeutics


Axogen to Participate at AAHS ASPN ASRM 2022 Annual Meetings

Axogen to Participate at AAHS ASPN ASRM 2022 Annual Meetings

(NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced its participation at the combined 2022 meetings of the American Association for Hand Surgery (AAHS), American Society for Peripheral Nerve (ASPN), and the American Society for Reconstructive ...

ByAxogen (AXGN)


Axogen sponsors 2022 Donate Life Rose Parade® Float to help raise awareness of organ and tissue donation

Axogen sponsors 2022 Donate Life Rose Parade® Float to help raise awareness of organ and tissue donation

(NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, announced today that nerve repair patient Christopher (Chris) Brown has been selected to ride on the 2022 Donate Life Rose Parade Float. ...

ByAxogen (AXGN)


Leonhardt’s Launchpads Accelerator to Showcase Eight Innovation Assets and Startups At 2022 Demo Day

Leonhardt’s Launchpads Accelerator to Showcase Eight Innovation Assets and Startups At 2022 Demo Day

The 2021 class of Leonhardt’s Launchpads Accelerator graduates include: MyoStim ED with ErectiStimTM: MyoStim ED is the first intervention for erectile dysfunction (ED) designed to address all major causes of ED: impaired blood flow, damaged blood vessels, nerve damage, and muscle deterioration. MyoStim ED utilizes non-invasive ...

BySecond Heart Assist, Inc.


Axogen, Inc. to Participate at Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum

Axogen, Inc. to Participate at Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum

About Axogen Axogen (AXGN) is the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral ...

ByAxogen (AXGN)


Axogen, Inc. to Participate at Jefferies London Healthcare Conference

Axogen, Inc. to Participate at Jefferies London Healthcare Conference

About Axogen Axogen (AXGN) is the leading company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral ...

ByAxogen (AXGN)


BlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson`s Disease

BlueRock Therapeutics Receives FDA Fast Track Designation for DA01 in the Treatment of Advanced Parkinson`s Disease

About Parkinson’s Disease Parkinson’s disease is a progressive neurodegenerative disorder caused by nerve cell damage in the brain, leading to decreased dopamine levels. ...

ByBlueRock Therapeutics


Research Finds Nearly 40% of Diabetes Patients who Suffer a Lower Extremity Amputation Endure Another Within Five Years

Research Finds Nearly 40% of Diabetes Patients who Suffer a Lower Extremity Amputation Endure Another Within Five Years

“Diabetes complications can include nerve damage and poor blood circulation, which make feet vulnerable to ulcers that, if left untreated, can lead to amputations. ...

ByPodimetrics Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT